Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel

Tim Kanters; Jelena Stevanovic; I Huys; Arnold Vulto; S Simoens

doi:10.3389/fphar.2017.00322

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel

Tim Kanters, Jelena Stevanovic, I Huys, Arnold Vulto, S Simoens

Research output: Contribution to journal › Article › Academic › peer-review

24 Citations (Scopus)

20 Downloads (Pure)

Original language	Undefined/Unknown
Article number	322
Journal	Frontiers in Pharmacology
Volume	8
DOIs	https://doi.org/10.3389/fphar.2017.00322
Publication status	Published - 2017

Research programs

EMC NIHES-05-63-02 Quality

Access to Document

10.3389/fphar.2017.00322

REPUB_108034_OA.pdfFinal published version, 2.35 MB

http://hdl.handle.net/1765/108034

Cite this

@article{24003523288a4318ac9e142754285ebc,

title = "Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel",

author = "Tim Kanters and Jelena Stevanovic and I Huys and Arnold Vulto and S Simoens",

year = "2017",

doi = "10.3389/fphar.2017.00322",

language = "Undefined/Unknown",

volume = "8",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel

AU - Kanters, Tim

AU - Stevanovic, Jelena

AU - Huys, I

AU - Vulto, Arnold

AU - Simoens, S

PY - 2017

Y1 - 2017

U2 - 10.3389/fphar.2017.00322

DO - 10.3389/fphar.2017.00322

M3 - Article

SN - 1663-9812

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

M1 - 322

ER -